24
views
0
recommends
+1 Recommend
3 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      A Framework for Biomarkers of COVID-19 Based on Coordination of Speech-Production Subsystems

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Goal: We propose a speech modeling and signal-processing framework to detect and track COVID-19 through asymptomatic and symptomatic stages. Methods: The approach is based on complexity of neuromotor coordination across speech subsystems involved in respiration, phonation and articulation, motivated by the distinct nature of COVID-19 involving lower (i.e., bronchial, diaphragm, lower tracheal) versus upper (i.e., laryngeal, pharyngeal, oral and nasal) respiratory tract inflammation, as well as by the growing evidence of the virus’ neurological manifestations. Preliminary results: An exploratory study with audio interviews of five subjects provides Cohen's d effect sizes between pre-COVID-19 (pre-exposure) and post-COVID-19 (after positive diagnosis but presumed asymptomatic) using: coordination of respiration (as measured through acoustic waveform amplitude) and laryngeal motion (fundamental frequency and cepstral peak prominence), and coordination of laryngeal and articulatory (formant center frequencies) motion. Conclusions: While there is a strong subject-dependence, the group-level morphology of effect sizes indicates a reduced complexity of subsystem coordination. Validation is needed with larger more controlled datasets and to address confounding influences such as different recording conditions, unbalanced data quantities, and changes in underlying vocal status from pre-to-post time recordings.

          Related collections

          Most cited references18

          • Record: found
          • Abstract: found
          • Article: not found

          Neurologic Features in Severe SARS-CoV-2 Infection

          To the Editor: We report the neurologic features in an observational series of 58 of 64 consecutive patients admitted to the hospital because of acute respiratory distress syndrome (ARDS) due to Covid-19. The patients received similar evaluations by intensivists in two intensive care units (ICUs) in Strasbourg, France, between March 3 and April 3, 2020. Six patients were excluded because of paralytic neuromuscular blockade when neurologic data were collected or because they had died without a neurologic examination having been performed. In all 58 patients, reverse-transcriptase–polymerase-chain-reaction (RT-PCR) assays of nasopharyngeal samples were positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The median age of the patients was 63 years, and the median Simplified Acute Physiology Score II at the time of neurologic examination was 52 (interquartile range, 37 to 65, on a scale ranging from 0 to 163, with higher scores indicating greater severity of illness). Seven patients had had previous neurologic disorders, including transient ischemic attack, partial epilepsy, and mild cognitive impairment. The neurologic findings were recorded in 8 of the 58 patients (14%) on admission to the ICU (before treatment) and in 39 patients (67%) when sedation and a neuromuscular blocker were withheld. Agitation was present in 40 patients (69%) when neuromuscular blockade was discontinued (Table 1). A total of 26 of 40 patients were noted to have confusion according to the Confusion Assessment Method for the ICU; those patients could be evaluated when they were responsive (i.e., they had a score of −1 to 1 on the Richmond Agitation and Sedation Scale, on a scale of −5 [unresponsive] to +4 [combative]). Diffuse corticospinal tract signs with enhanced tendon reflexes, ankle clonus, and bilateral extensor plantar reflexes were present in 39 patients (67%). Of the patients who had been discharged at the time of this writing, 15 of 45 (33%) had had a dysexecutive syndrome consisting of inattention, disorientation, or poorly organized movements in response to command. Magnetic resonance imaging (MRI) of the brain was performed in 13 patients (Figs. S1 through S3 in the Supplementary Appendix, available with the full text of this letter at NEJM.org). Although these patients did not have focal signs that suggested stroke, they underwent MRI because of unexplained encephalopathic features. Enhancement in leptomeningeal spaces was noted in 8 patients, and bilateral frontotemporal hypoperfusion was noted in all 11 patients who underwent perfusion imaging. Two asymptomatic patients each had a small acute ischemic stroke with focal hyperintensity on diffusion-weighted imaging and an overlapping decreased apparent diffusion coefficient, and 1 patient had a subacute ischemic stroke with superimposed increased diffusion-weighted imaging and apparent diffusion coefficient signals. In the 8 patients who underwent electroencephalography, only nonspecific changes were detected; 1 of the 8 patients had diffuse bifrontal slowing consistent with encephalopathy. Examination of cerebrospinal fluid (CSF) samples obtained from 7 patients showed no cells; in 2 patients, oligoclonal bands were present with an identical electrophoretic pattern in serum, and protein and IgG levels were elevated in 1 patient. RT-PCR assays of the CSF samples were negative for SARS-CoV-2 in all 7 patients. In this consecutive series of patients, ARDS due to SARS-CoV-2 infection was associated with encephalopathy, prominent agitation and confusion, and corticospinal tract signs. Two of 13 patients who underwent brain MRI had single acute ischemic strokes. Data are lacking to determine which of these features were due to critical illness–related encephalopathy, cytokines, or the effect or withdrawal of medication, and which features were specific to SARS-CoV-2 infection.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found

            Association of chemosensory dysfunction and Covid‐19 in patients presenting with influenza‐like symptoms

            Abstract Background Rapid spread of the SARS‐CoV‐2 virus and concern for viral transmission by ambulatory patients with minimal to no symptoms underline the importance of identifying early or subclinical symptoms of Covid‐19 infection. Two such candidate symptoms include anecdotally reported loss of smell and taste. Understanding the timing and association of smell/taste loss in Covid‐19 may help facilitate screening and early isolation of cases. Methods A single‐institution, cross‐sectional study evaluating patient‐reported symptoms with a focus on smell and taste was conducted using an internet‐based platform on adult subjects who underwent testing for Covid‐19. Logistic regression was employed to identify symptoms associated with Covid‐19 positivity. Results A total of 1480 patients with influenza‐like symptoms underwent Covid‐19 testing between March 3 through 29, 2020. Our study captured 59 of 102 (58%) Covid‐19‐positive patients and 203 of 1378 (15%) Covid‐19‐negative patients. Smell and taste loss were reported in 68% (40/59) and 71% (42/59) of Covid‐19‐positive subjects, respectively, compared to 16% (33/203) and 17% (35/203) of Covid‐19‐negative patients (p<0.001). Smell and taste impairment were independently and strongly associated with Covid‐19‐positivity (anosmia: adjusted odds ratio [aOR] 10.9, 95%CI:5.08‐23.5; ageusia: aOR 10.2 95%CI:4.74‐22.1); whereas, sore throat was associated with Covid‐19‐negativity (aOR 0.23, 95%CI:0.11‐0.50). Of patients who reported Covid‐19‐associated loss of smell, 74% (28/38) reported resolution of anosmia with clinical resolution of illness. Conclusions In ambulatory individuals with influenza‐like symptoms, chemosensory dysfunction was strongly associated with Covid‐19 infection and should be considered when screening symptoms. Most will recover chemosensory function within weeks paralleling resolution of other disease‐related symptoms. This article is protected by copyright. All rights reserved
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found

              A New Symptom of COVID‐19: Loss of Taste and Smell

              To the Editor: As the ongoing COVID‐19 pandemic rapidly progresses across the globe, quickly obtaining accurate information on symptoms and their progression is vital. Since most affected patients have mild to no symptoms, it remains crucial to quickly relate any commonly observed symptoms and to do so widely. Cough, fever, and/or trouble breathing are the major symptoms that have been publicly communicated in a consistent manner. Meanwhile, the people with the greatest knowledge of current symptoms are the healthcare workers in the countries being most affected (e.g. Italy, France, Iran), yet they also have the least time to transmit this important information to the greater public. One of the authors (Jean‐François Gautier), an endocrinologist in Paris, has transformed his Diabetes and Endocrinology inpatient beds at l’Hopital Lariboisiere, as have other specialized units, into an inpatient unit totally dedicated to COVID‐19‐positive patients. His recent interactions with patients and other doctors have rapidly led to the realization that sudden loss of smell (anosmia) and/or taste (ageusia) may be experienced in the infected, symptoms not commonly reported in China. The other author (Yann Ravussin), an obesity researcher currently living in Geneva, has recently experienced a rapid onset of anosmia following 2 to 3 days of strong fatigue and headache. Having presented no fever, coughing, or breathing problems, he initially decided that COVID‐19 was unlikely based on readily available news outlets and official governmental websites (CDC, Swiss Government Health) yet was subsequently told he likely had the virus but did not reach the criteria for testing based on age and/or symptoms. Yet it is slowly emerging that these symptoms are quite common. Anosmia has been reported to be found in upwards of 2/3 of patients in Germany by epidemiologist Hendrik Streek (1) while Italian and Swiss doctors are reporting similar findings with many also displaying ageusia. Numbers from South Korea suggest that 30% of positive patients had anosmia as the primary presenting symptom. Dr. Ravussin’s frustration on the paucity of information related to the anosmia found online and in normal media outlets pushed him to contact various medical doctors directly working with infected patients on three continents and all confirmed that this presenting symptom is common knowledge within the medical professional communities directly fighting the COVID‐19 virus. We are writing to the Editors to make sure this information is more widely circulated among readers of the Journal and hope/suggest that people who present with anosmia and/or ageusia without other symptoms are admitted for testing and realize that they may be affected by the current pandemic. This moment in our lives will be complicated, stressful, and full of unknowns but with better knowledge transfer should come better decision‐making to keep us and our loved ones safe.
                Bookmark

                Author and article information

                Contributors
                Journal
                IEEE Open J Eng Med Biol
                IEEE Open J Eng Med Biol
                0076400
                OJEMB
                IOJEA7
                IEEE Open Journal of Engineering in Medicine and Biology
                IEEE
                2644-1276
                2020
                29 May 2020
                : 1
                : 203-206
                Affiliations
                [ 1 ] institutionMIT Lincoln Laboratory, institutionringgold 57663; Lexington MA 02421 USA
                [ 2 ] divisionHarvard-MIT Speech and Hearing Bioscience and Technology Program, institutionHarvard Medical Sciences, institutionringgold 438871; Boston MA 02115 USA
                [ 3 ] institutionMIT Lincoln Laboratory, institutionringgold 57663; Lexington MA 02421 USA
                Article
                10.1109/OJEMB.2020.2998051
                8975176
                35402959
                d28315d3-1b14-416c-822f-2e66ab65c491
                Copyright @ 2020

                This work is licensed under a Creative Commons Attribution 4.0 License. For more information, see https://creativecommons.org/licenses/by/4.0/

                History
                : 09 April 2020
                : 06 May 2020
                : 07 May 2020
                : 29 July 2020
                Page count
                Figures: 3, Tables: 0, References: 19, Pages: 4
                Funding
                Funded by: institutionUnder Secretary of Defense for Research and Engineering;
                Award ID: FA8702-15-D-0001
                Funded by: institutionNIH;
                Funded by: institutionNIDCD;
                Award ID: T32 DC000038
                This work was supported by the Under Secretary of Defense for Research and Engineering under Air Force Contract No. FA8702-15-D-0001. The work of T. Talkar was supported in part by NIH-NIDCD T32 DC000038.
                Categories
                Article

                asymptomatic,covid-19,respiration,vocal subsystems,motor coordination

                Comments

                Comment on this article